再看低甲基化药物治疗后继发性急性髓系白血病的现状
A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents.
作者信息
Peters Daniel T, Zeidner Joshua F
机构信息
University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
出版信息
Cancer. 2025 Apr 15;131(8):e35838. doi: 10.1002/cncr.35838.
Abstract
This editorial highlights the significant clinical challenges and poor outcomes faced by patients with secondary AML after prior hypomethylating agent therapy (HMA-sAML), underscoring the urgent need for novel treatments. The authors emphasize that current standard therapies remain inadequate, calling for clinical trials tailored specifically to address the unique biological complexity and therapeutic resistance observed in this patient population
摘要
这篇社论强调了接受过甲基化抑制剂治疗后的继发性急性髓系白血病患者（HMA-sAML）所面临的重大临床挑战和不良预后，突显了对新型治疗方法的迫切需求。作者强调，目前的标准疗法仍然不足，呼吁开展专门针对该患者群体中观察到的独特生物学复杂性和治疗耐药性的临床试验。
相似文献
1
A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents.再看低甲基化药物治疗后继发性急性髓系白血病的现状
Cancer. 2025 Apr 15;131(8):e35838. doi: 10.1002/cncr.35838.
2
Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.比较 70 岁及以上急性髓系白血病患者常用一线方案的生存结局。
Haematologica. 2020 Jan 31;105(2):398-406. doi: 10.3324/haematol.2018.208637. Print 2020.
3
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.骨髓增生异常综合征相关急性髓系白血病患者接受诱导化疗后的结果。
Cancer. 2011 Apr 1;117(7):1463-9. doi: 10.1002/cncr.25598. Epub 2010 Nov 8.
4
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.口服低甲基化剂在急性髓系白血病和骨髓增生异常综合征中的研发和临床应用：全口服治疗时代的曙光。
Expert Rev Anticancer Ther. 2021 Sep;21(9):989-1002. doi: 10.1080/14737140.2021.1918002. Epub 2021 Apr 28.
5
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.维奈托克联合低甲基化药物治疗初治 B/髓系混合表型急性白血病和复发/难治性急性髓系白血病：3 例报告。
Chemotherapy. 2022;67(3):178-182. doi: 10.1159/000519882. Epub 2022 Mar 18.
6
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.去甲基化药物治疗后发生的继发性急性髓系白血病的治疗模式与预后：PETHEMA注册研究
Cancer. 2025 Jan 1;131(1):e35696. doi: 10.1002/cncr.35696.
7
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.异基因干细胞移植前使用去甲基化药物治疗可改善慢性粒单核细胞白血病患者的无进展生存期。
Biol Blood Marrow Transplant. 2016 Jan;22(1):47-53. doi: 10.1016/j.bbmt.2015.08.031. Epub 2015 Sep 4.
8
Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.急性髓系白血病伴骨髓增生异常相关改变患者经去甲基化药物治疗后出现17号染色体等臂染色体的病例报告。
Genet Mol Res. 2012 Aug 6;11(3):2045-50. doi: 10.4238/2012.August.6.8.
9
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax.继发性急性髓系白血病和早期感染是接受去甲基化药物和维奈克拉治疗的急性髓系白血病患者生存不良的独立预测因素。
Hematol Oncol. 2024 Sep;42(5):e3310. doi: 10.1002/hon.3310.
10
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.比较先前存在的髓系恶性肿瘤患者对低甲基化药物耐药后急性髓系白血病患者的诱导策略和反应。
Leuk Res. 2020 Jun;93:106367. doi: 10.1016/j.leukres.2020.106367. Epub 2020 May 1.
本文引用的文献
1
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.奥芦他定尼联合阿扎胞苷可使复发或难治性mIDH1急性髓系白血病患者实现持久完全缓解：一项多队列开放标签1/2期试验
J Hematol Oncol. 2025 Jan 16;18(1):7. doi: 10.1186/s13045-024-01657-z.
2
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.去甲基化药物治疗后发生的继发性急性髓系白血病的治疗模式与预后：PETHEMA注册研究
Cancer. 2025 Jan 1;131(1):e35696. doi: 10.1002/cncr.35696.
3
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.阿扎胞苷与维奈克拉联合或不联合pevonedistat用于新诊断的急性髓系白血病患者。
Leuk Lymphoma. 2025 Mar;66(3):458-468. doi: 10.1080/10428194.2024.2431878. Epub 2024 Nov 28.
4
How I treat secondary acute myeloid leukemia.我如何治疗继发性急性髓系白血病。
Blood. 2025 Mar 20;145(12):1260-1272. doi: 10.1182/blood.2024024011.
5
Menin Inhibition With Revumenib for -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).使用瑞武尼布抑制Menin治疗重排的复发或难治性急性白血病（AUGMENT-101）。
J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9.
6
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory -Mutated AML.阿扎胞苷、维奈托克和吉特替尼治疗新诊断和复发/难治性 - 突变 AML。
J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26.
7
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Venetoclax 与阿扎胞苷联合治疗复发或难治性骨髓增生异常综合征患者的 1b 期研究。
Am J Hematol. 2023 Feb;98(2):272-281. doi: 10.1002/ajh.26771. Epub 2022 Nov 10.
8
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.吉特替尼联合阿扎胞苷与阿扎胞苷治疗新诊断的不适合强化化疗的 FLT3 突变阳性 AML 的 3 期临床试验。
Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586.
9
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
10
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
Zotero 插件